NGS

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Retrieved on: 
Monday, January 8, 2024

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

Key Points: 
  • The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
  • This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.
  • Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.
  • Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Retrieved on: 
Monday, January 8, 2024

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

Key Points: 
  • The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
  • This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.
  • Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.
  • Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

Retrieved on: 
Sunday, January 7, 2024

SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.

Key Points: 
  • SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
  • The Company shipped eight G4 instruments in the fourth quarter of 2023.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765 thousand during the fourth quarter of 2022.
  • Singular Genomics plans to release its full fourth quarter and 2023 financial results in March 2024.

QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

Retrieved on: 
Thursday, January 4, 2024

Venlo, the Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business.

Key Points: 
  • Venlo, the Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business.
  • These investments will support QDI, the bioinformatics market leader with sales of approximately $100 million in 2023, to expand its offerings in new geographic regions and market segments while delivering enhanced customer insights and new products.
  • “Our significant investments into QDI demonstrate our commitment to accelerating growth and promoting innovation in the bioinformatics market.
  • Importantly, QDI’s Knowledge Base allows biologists to drive confident analysis and interpretation without requiring bioinformatics expertise.

Burning Rock Announces Receipt of Notification from NASDAQ

Retrieved on: 
Thursday, January 4, 2024

The NASDAQ notification letter has no current effect on the listing or trading of the Company’s securities on NASDAQ.

Key Points: 
  • The NASDAQ notification letter has no current effect on the listing or trading of the Company’s securities on NASDAQ.
  • Pursuant to the NASDAQ Listing Rules 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 26, 2024, to regain compliance with NASDAQ’s minimum bid price requirement.
  • The Company’s business operations are not affected by the NASDAQ notification letter.
  • The Company intends to monitor the closing bid price of its ADSs between now and June 26, 2024 and will take all reasonable measures in order to regain compliance with the NASDAQ minimum bid price requirement.

DeciBio Forecasts the Global Clinical Oncology Biomarker Testing Market to Grow at 13% p.a., Reaching ~$12.6B in 2028 - Market Report by DeciBio Consulting LLC

Retrieved on: 
Wednesday, January 3, 2024

DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.

Key Points: 
  • DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.
  • The second edition of DeciBio’s Clinical Oncology Biomarker Testing Report takes a comprehensive look at biomarker testing for patient stratification, therapy selection, and prognosis for cancer treatment globally, including both products (kits) and services.
  • NGS, PCR, and IHC are the primary technologies utilized for clinical biomarker testing today.
  • Increased access to each of these technologies, as well as to the precision medicines requiring testing, is expected to drive significant growth of the biomarker testing market in the near-mid term.

Molecular Diagnostics Research That Could Transform Healthcare Featured in the January Issue of ADLM's The Journal of Applied Laboratory Medicine

Retrieved on: 
Wednesday, January 3, 2024

This special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) The Journal of Applied Laboratory Medicine highlights the latest research in this field that could advance care for conditions ranging from infectious diseases to inherited disorders.

Key Points: 
  • This special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) The Journal of Applied Laboratory Medicine highlights the latest research in this field that could advance care for conditions ranging from infectious diseases to inherited disorders.
  • The COVID-19 pandemic is the most striking recent example of the central role of molecular diagnostics in global health.
  • And pandemic management isn't the only area of infectious disease testing that molecular diagnostic technology is revolutionizing.
  • Broadening access to personalized medicine is another goal of modern healthcare that wouldn't be possible without molecular diagnostics.

HydroGraph’s Graphene Selected by Hawkeye Bio for Use in its Early-Stage Lung Cancer Detection Biosensor

Retrieved on: 
Wednesday, January 3, 2024

HydroGraph’s graphene, the third company to be certified globally by the Graphene Council, was selected by Hawkeye Bio based on the purity and consistency of its graphene.

Key Points: 
  • HydroGraph’s graphene, the third company to be certified globally by the Graphene Council, was selected by Hawkeye Bio based on the purity and consistency of its graphene.
  • The sensor also improves the patient experience by using non-invasive biological samples, such as blood, urine, saliva or exhaled breath, in early-stage lung cancer testing.
  • “Hawkeye Bio leverages HydroGraph’s pristine graphene to manufacture pharmaceutical grade biosensors for the detection of lung cancer from a standard blood draw.
  • “After several years of working together with Hawkeye, we have developed a strong partnership and are thrilled that our graphene helped bring their biosensor to market to save lives.”

Global Transplant Diagnostics (HLA, Blood Profile, Pathogen Detection) Market Research Report 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023

The "Global Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The transplant diagnostic market is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4%.
  • This report studies the transplant diagnostic market based on product & service, technology, application, end user, and region.
  • It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders.

Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research

Retrieved on: 
Thursday, December 28, 2023

SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease.

Key Points: 
  • SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease.
  • The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July 2023, further advance OGM’s leadership in variant detection.
  • Together with the enhanced performance for SV and CNV calling, VIA software now enables the most comprehensive visualization, interpretation and reporting of SVs and CNVs from OGM data in constitutional genetic disease research.
  • The progress announced today helps the constitutional genetic disease research community go beyond the capabilities of Bionano Access™ software in a way that significantly improves their ability to visualize, interpret and report results in a streamlined process that runs faster than ever.